Safety Study of GCS-100 to Treat Chronic Kidney Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Chronic Kidney Disease
Interventions
DRUG

GCS-100

GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).

Trial Locations (4)

78215

Renal Associates PA / Research Division, San Antonio

80230

Denver Nephrologists, PC, Denver

85284

Southwest Clinical Research Institute, Tempe

91942

California Institue of Renal Research, La Mesa

All Listed Sponsors
lead

La Jolla Pharmaceutical Company

INDUSTRY

NCT01717248 - Safety Study of GCS-100 to Treat Chronic Kidney Disease | Biotech Hunter | Biotech Hunter